In this episode of Learn Something with Thaena, we explore one of the most promising developments in microbiome oncology: whether reshaping the gut microbiome can improve response to cancer immunotherapy. We unpack the new FMT-LUMINate trial, a phase 2 study in patients with non-small cell lung cancer and melanoma, where a single dose of fecal microbiota transplant given before checkpoint inhibitor therapy was associated with striking response rates. But the most interesting finding was not simply donor bacteria “engrafting.” Instead, responders appeared to lose specific baseline bacterial species linked to resistance, suggesting that therapeutic benefit may come from removing deleterious microbes and restoring a more immune-supportive metabolic environment. We also discuss the earlier studies that built this field, the role of antibiotics, and why metabolites, not just microbes, may be the real mechanistic story.

Paper referenced:
Duttagupta S, Messaoudene M, Hunter S, et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nature Medicine. 2026. doi:10.1038/s41591-025-04186-5.

In this episode of Learn Something with Thaena, we explore a striking new discovery in microbiome science: gut bacteria may help activate 5-ASA, a longstanding therapy used in inflammatory bowel disease. Drawing on a new preprint by Lamoureux and colleagues, we unpack how microbes can conjugate 5-ASA to bile acids, creating hybrid compounds such as cholyl-5-ASA that showed stronger anti-inflammatory activity than 5-ASA alone in cell assays and a mouse colitis model. The finding reframes a familiar drug as part of a larger microbial-host co-metabolic process, and raises a bigger question: how many other medications depend on the microbiome to work as intended?

Paper referenced:
Charron-Lamoureux V, Kelly P, Zuffa S, et al. Pan-repository analysis reveals a drug-activating function of microbial bile acid conjugation. bioRxiv. Posted March 4, 2026. doi: 10.64898/2026.03.03.709330.

Okay, real talk.

Have you ever taken an antibiotic, felt better in four days, and then completely forgot it ever happened?

Your gut definitely hasn't forgotten. A brand new 2026 study of nearly 15,000 Swedish adults just showed that a single course of antibiotics can leave a measurable mark on your gut microbiome for up to eight years. Clindamycin alone was associated with losing 47 species from one course. And the recovery curve? It flattens after two years — meaning if those species haven't come back by then, they probably aren't coming back. In this Lit Review Friday episode, we break down Baldanzi et al. (2026) from Nature Medicine, connect it to the landmark Suez et al. (2018) Cell study on why probiotics might actually delay recovery, and lay out what the science says about how to actually support your gut before, during, and after antibiotics.

🎙️ Hosted by AI Andrea and AI Jennifer Learn Something with Thaena uses AI to distill cutting-edge microbiome and health science into insights that are approachable, thought-provoking, and actionable.

🔬 Primary paper: Baldanzi G, et al. "Oral antibiotic use and the gut microbiome." Nature Medicine, 2026.

🌐 thaena.com